Taxon Biosciences

About Taxon Biosciences

Taxon Biosciences, founded in 2000 by microbial geneticists Matt Ashby and Jasper Rine, operated as a biotechnology firm specializing in microbial genomics. The company was established with the goal of creating a microbial genomics platform to address significant challenges in the agriculture, energy, and health science sectors. Based in Tiburon, California, Taxon Biosciences focused on utilizing proprietary advancements in genomics, bioinformatics, and microbiology. Its core business involved identifying, validating, and commercializing microbiome-based products derived from agricultural and environmental settings.

The company's primary service was to profile microbial communities using genomic tools to understand their structure and function. This involved conducting in-depth diversity profiles of selected sites to identify specific DNA sequences correlated with parameters of interest, such as the presence of certain gases or salinity levels. From this data, the firm developed quantitative assays for these indicator species, which could then be used in broader bioindicator surveys. The business catered to a range of markets, including the energy sector and clinical diagnostics. Its technology and extensive intellectual property portfolio in microbial consortia and genomics were geared towards developing new products like seed treatments, as well as foliar and soil applications for major row crops, fruits, and vegetables.

A significant milestone in the company's history was its acquisition by DuPont in April 2015 for an undisclosed sum. This acquisition was a strategic move by DuPont to enhance its in-house capabilities in biological solutions for the agriculture industry, complementing its existing seed and crop protection businesses. Prior to the acquisition, Taxon Biosciences had secured $4.01 million in a Series A funding round in April 2013, with investors including Formation 8, BP Ventures, and ConocoPhillips Technology Ventures. The integration into DuPont was intended to accelerate the discovery-to-market timeline for new biological products.